Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017.
Phase of Trial: Phase III
Latest Information Update: 25 Sep 2017
At a glance
- Drugs Fexapotide (Primary)
- Indications Benign prostatic hyperplasia
- Focus Registrational; Therapeutic Use
- Acronyms NEXUS-1
- Sponsors Nymox Pharmaceutical Corporation
- 25 Sep 2017 According to a Nymox Pharmaceutical media release, data will be presented at American Urological Association Meeting.
- 31 May 2017 Results of pooled analysis of data from phase III trials (NX02-0017, NX02-0018, NX02-0020 and NX02-0022) evaluating standardized Sexual Function Questionnaire (SFQ) published in a Nymox Pharmaceutical Corporation media release.
- 29 Nov 2016 Results of pooled analysis of data from phase 3 trials (NX02-0017, NX02-0018, NX02-0020 and NX02-0022) published in a Nymox Pharmaceutical Corporation.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History